Princeton, New Jersey-based Oyster Point Pharma, a clinical-stage biopharmaceutical company focusing on treating ocular surface diseases, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol "OYST." J.P. Morgan Securities LLC, Cowen & Company LLC and Piper Jaffray & Co. will serve as the lead underwriters. Oyster Point's backers include Invus Opportunities and Flying L Partners.
Woburn, Massachusetts-based Frequency Therapeutics, a biotech firm, has raised about $84 million for its IPO after pricing its 6 million share at $14 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "FREQ." J.P. Morgan, Goldman Sachs and Cowen are the lead underwriters. Frequency's pre-IPO backers include Perceptive Advisors.
Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has raised about $85 million for its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "APRE." J.P. Morgan, Morgan Stanley and RBC Capital Markets are the lead underwriters. Aprea's pre-IPO backers include Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
ADC Therapeutics, a Swiss cancer drug developer, has postponed its U.S. IPO, citing adverse conditions, reported Reuters. The firm was planning on raising $200 million for the IPO. ADC's backers include Auven Therapeutics and AstraZeneca.
Peloton Interactive raised $1.16 billion after selling 40 million shares at $29 each, at the top end of its $26 to $29 price range, an SEC filing said. Peloton provides on-demand workout programs on its exercise bikes, the filing said.
BioNTech SE, a German biotech company focused on treating cancer and other serious diseases, is planning on raising about $250 million for its IPO after pricing its 13.2 million shares at a price between $18 and $20 per share. The company plans on trading the stock on the NASDAQ under the ticker symbol "BNTX." J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink are the lead underwriters. BioNTech's investors include Fidelity Management & Research Company.
Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has priced its IPO of 5 million shares between $14 and $16 per share. Aprea is backed by Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
Ping Identity, a provider of intelligent identity solutions, has gone public after pricing its 12.5 million shares at $15 per share. The stock began trading September 19, 2019 on the New York Stock Exchange under the ticker symbol "PING." Goldman Sachs, BofA Merrill Lynch, RBC Capital Markets and Citigroup are the lead underwriters. Ping Identity is backed by Vista Equity Partners.
California-based Exagen Inc, a provider of advanced rheumatology testing, has debuted its IPO after pricing its 3.6 million shares at $14 per share. The stock began trading September 19, 2019 on the NASDAQ under the ticker symbol "XGN." Cowen and Company LLC, Cantor Fitzgerald and William Blair are the lead underwriters. Exagen's pre-IPO backers included H.I.G. Capital, Tullis Health Funds, Sun Mountain and Hunt Holdings.
Brea, California-based Envista, a dental products company being spun out of Danaher, raised over $588 million for its IPO after pricing its over 26.7 million shares at $22 per share. The stock began trading September 18, 2019 on the New York Stock Exchange under the ticker symbol "NVST." J.P. Morgan, Goldman Sachs and Morgan Stanley are the lead underwriters.